ReviewFrontiers in immunology2024
Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trophoblast Extracellular Vesicles Rewire Immunity: A Symptom-Relief Avenue for Recessive Dystrophic Epidermolysis Bullosa.Journal of extracellular vesicles · 2026Article
- H19 and the PD-1/PD-L1 Axis in hepatocellular carcinoma and colorectal cancer: emerging evidence, mechanistic links, and therapeutic perspectives.Clinical and experimental medicine · 2026Review
- Exosomes and lung cancer: Biogenesis, pathogenic mechanisms, biomarkers, and therapeutic applications.The Journal of international medical research · 2026Review
- Exosomes liquid biopsy in Lymphoma precision medicine: applications and challenges.Cancer cell international · 2026Review
- Core regulatory mechanisms of the PD-L1 axis and clinical strategies for immune escape and immunotherapy response in nasopharyngeal carcinoma.Translational oncology · 2026Review
- Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells.British journal of cancer · 2026Article
- Simple and rapid profiling of tumor EVs for differential diagnosis of NSCLC via orthogonal barcode-driven CRISPR/Cas12a.Journal of nanobiotechnology · 2026Article
- Review
- Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective.Frontiers in immunology · 2026Review
- EV-associated HOTAIR in cancer cell communication: a distance-aware review of functional transfer claims.Frontiers in cell and developmental biology · 2026Review
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- eIF4E Enriched Extracellular Vesicles Induce Immunosuppressive Macrophages through HMGCR-Mediated Metabolic Rewiring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.Journal of nanobiotechnology · 2025Review
- Establishment of an Assay with Ultrahigh Sensitivity for Detecting sEV-Derived PD-L1 as a Serum Biomarker for Lung Cancer-A Pilot Study Using TN-cyclon™.Current issues in molecular biology · 2025Article
- Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy.Current issues in molecular biology · 2025Review
- Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects.Cancer cell international · 2025Review
- Unraveling exosome-mediated cancer therapy resistance: pathways and therapeutic challenges.Journal of the Egyptian National Cancer Institute · 2025Review
- Exosome-based immunotherapy in hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.Clinical and experimental medicine · 2025Review
- Exosomes in review: A new frontier in CAR-T cell therapies.Neoplasia (New York, N.Y.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD-1/PD-L1 signaling is a key factor of local immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors targeting PD-1/PD-L1 signaling have achieved tremendous success in clinic. However, several types of cancer are particularly refractory to the anti-PD-1/PD-L1 treatment. Recently, a series of studies reported that IFN-γ can stimulate cancer cells to release exosomal PD-L1 (exoPD-L1), which possesses the ability to suppress anticancer immune responses and is associated with anti-PD-1 response. In this review, we introduce the PD-1/PD-L1 signaling, including the so-called 'reverse signaling'. Furthermore, we summarize the immune treatments of cancers and pay more attention to immune checkpoint inhibitors targeting PD-1/PD-L1 signaling. Additionally, we review the action mechanisms and regulation of exoPD-L1. We also introduce the function of exoPD-L1 as biomarkers. Finally, we review the methods for analyzing and quantifying exoPD-L1, the therapeutic strategies targeting exoPD-L1 to enhance immunotherapy and the roles of exoPD-L1 beyond cancer. This comprehensive review delves into recent advances of exoPD-L1 and all these findings suggest that exoPD-L1 plays an important role in both cancer and other fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.